drug development

May 23, 2023

Treating kidney injury before it happens

Pretreatment of an animal model with a novel compound called PHAD reduced kidney injury, suggesting it may be a good candidate for preventing kidney injury in surgical patients.

By Sarah E. Glass
July 11, 2022

A speedier treatment for depression?

Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.

By Paul Govern
July 8, 2019

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

By Leigh MacMillan
April 11, 2019

The arrestin-GPCR connection

Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular “inboxes” that are targeted by up to half of all pharmaceuticals.

By Sanjay Mishra
April 28, 2017

Regulating anxiety in the brain

Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both.

By Leigh MacMillan
elderly Asian mother and adult daughter
April 27, 2017

Protein structure may aid in treating Alzheimer’s disease

A new protein structure may guide the development of Alzheimer’s therapeutics.

By Leigh MacMillan
August 20, 2015

New type of trial shows promise for several cancers

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.
By VUMC News and Communications